TRAIL-Induced Apoptosis Between Tumor Therapy and Immunopathology
TRAIL-Induced Apoptosis Between Tumor Therapy and Immunopathology
复制标题
DOI：
10.1111/j.1749-6632.2009.04905.x
复制
发表时间：
2009-01-01
期刊：
影响因子：
--
通讯作者：
Brunner, Thomas
中科院分区：
文献类型：
--
作者：
Corazza, Nadia;Kassahn, Daniela;Brunner, Thomas
肿瘤坏死因子(TNF)家族的死亡配体成员是多种细胞类型中有效的凋亡诱导剂。尤其是肿瘤坏死因子相关的凋亡诱导配体(TRAIL)，由于其强大的肿瘤细胞杀伤活性而使正常未转化细胞基本不受影响，近年来受到了科学和商业领域的广泛关注。此外，TRAIL与常规化疗药物在诱导肿瘤细胞凋亡方面具有很强的协同作用，使其成为未来最有希望的癌症治疗候选药物。然而，越来越多的证据表明，TRAIL也可能诱导或调节原代细胞的凋亡。一个特别令人担忧的问题是基于TRAIL的肝脏肿瘤治疗的潜在副作用。本文综述了TRAIL在肿瘤细胞和肝细胞凋亡中作用的一些最新研究结果。
The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.